Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction

Abstract: Growing evidence suggests that proinflammatory responses will be a crucial issue for developing neuropsychiatric disorders. Recent clinical trials demonstrated that adjunctive therapy of cyclo-oxygenase (COX)-2 inhibitor was effective for major depression. Here, we present the case of an elderly depressed woman with acute cognitive deficit who was refractory to multiple antidepressants but only responsive to celecoxib, a COX-2 inhibitor, in acute treatment and sustaining remission for a 5-year treatment course. Our finding suggests that a therapeutic effect of celecoxib exists for major depressive disorder comorbid with neurocognitive dysfunction. [Copyright &y& Elsevier]